Biotechnology and immunotherapy / Founded 2008
BioNTech
Immune-system platforms for individualized medicine
Company Record
BioNTech develops immunotherapies and messenger-RNA platforms, beginning with cancer research and later applying the same scientific foundation to an mRNA COVID-19 vaccine developed with Pfizer.
Milestones
- 2008BioNTech was founded in Mainz.
- 2019The company completed its public offering.
- 2020Project Lightspeed produced an mRNA COVID-19 vaccine candidate in partnership with Pfizer.
- 2021The vaccine was deployed globally while BioNTech continued its cancer pipeline.
Continue through the archive
One record should open another.
Follow the shared decisions, markets, constraints, and places surrounding this story.
01 / Ledger case fileOzlem Tureci: When Science Becomes SanctuaryOzlem Tureci helped build BioNTech in relative scientific obscurity before its messenger-RNA platform became central to the first widely deployed COVID-19 vaccines.20 minute read02 / Founder recordOzlem TureciOzlem Tureci carried lessons from an immigrant medical family into BioNTech: maintain scientific standards before recognition arrives, and build platforms that can move when the evidence changes.BioNTech / Mainz, Germany03 / Field noteThe Immigrant Founder's Outsider AdvantageCrossing systems and cultures can make normalized friction visible and produce unusually global founder networks.Founder Perspective04 / Company recordAnima IrisAfrican luxury, designed and produced with ownershipLuxury fashion and accessories / Founded 2019